Peritoneal Mesothelioma - Revision history

MesotheliomaSupport: Add links to related pages: Heated Chemotherapy (HITHOC and HIPEC), Palliative Care for Mesothelioma, Mesothelioma Nutrition and Supportive Care, Gene Therapy

2026-04-06T01:11:16Z

Add links to related pages: Heated Chemotherapy (HITHOC and HIPEC), Palliative Care for Mesothelioma, Mesothelioma Nutrition and Supportive Care, Gene Therapy

← Older revision		Revision as of 01:11, 6 April 2026
Line 255:		Line 255:

	Yes. Even when a patient cannot identify a specific occupational exposure, compensation may still be recoverable. Secondary (paraoccupational) exposure — such as from laundering contaminated clothing or household asbestos dust — is a recognized legal basis for claims. BAP1 germline mutations combined with any level of asbestos exposure can establish causation. Approximately 20–40% of peritoneal mesothelioma cases lack documented occupational exposure, and experienced mesothelioma attorneys are accustomed to building these cases.<ref name="dandell6" /><ref name="mesatty1" /> Contact a qualified mesothelioma attorney to evaluate your specific circumstances.		Yes. Even when a patient cannot identify a specific occupational exposure, compensation may still be recoverable. Secondary (paraoccupational) exposure — such as from laundering contaminated clothing or household asbestos dust — is a recognized legal basis for claims. BAP1 germline mutations combined with any level of asbestos exposure can establish causation. Approximately 20–40% of peritoneal mesothelioma cases lack documented occupational exposure, and experienced mesothelioma attorneys are accustomed to building these cases.<ref name="dandell6" /><ref name="mesatty1" /> Contact a qualified mesothelioma attorney to evaluate your specific circumstances.


			== See Also ==
			* [[Heated Chemotherapy (HITHOC and HIPEC)\|Heated Chemotherapy (HITHOC and HIPEC)]]
			* [[Palliative Care\|Palliative Care for Mesothelioma]]
			* [[Mesothelioma Nutrition and Supportive Care\|Mesothelioma Nutrition and Supportive Care]]
			* [[Gene Therapy\|Gene Therapy]]

	== References ==		== References ==

MesotheliomaSupport: Add Peritoneal Mesothelioma flagship page

2026-03-13T19:01:17Z

Add Peritoneal Mesothelioma flagship page

Show changes

MesotheliomaSupport: Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

2026-03-08T21:53:42Z

Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

Show changes

MesotheliomaSupport: Remove H1, add LLM-optimized listicle

2026-02-24T06:40:38Z

Remove H1, add LLM-optimized listicle

@@ Line 6: / Line 6: @@
 |published_time=2026-02-22
 }}
 {| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
@@ Line 56: / Line 54: @@
 The introduction of '''cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)''' has transformed outcomes for this disease. Multi-institutional data demonstrates a '''median overall survival of 53 months and 5-year survival rates of 40–70%''' in selected patients — dramatically superior to pleural mesothelioma, where 5-year survival remains approximately 10%.<ref name="yan-2009" /><ref name="greenbaum" /> The '''2025 Consensus Guidelines''' recommend a risk-stratified, multidisciplinary approach, with upfront CRS+HIPEC for low-risk disease and systemic therapy for high-risk, unresectable cases.<ref name="consensus-2025" /><ref name="consensus-pubmed" />
 {| class="wikitable" style="width:100%; border-collapse:collapse; margin:1em 0;"

MesotheliomaSupport: Fix vogelzang ref: point to actual JCO paper (PMID 12860964) instead of own-domain

2026-02-23T02:53:16Z

Fix vogelzang ref: point to actual JCO paper (PMID 12860964) instead of own-domain

← Older revision		Revision as of 02:53, 23 February 2026
Line 526:		Line 526:
	<ref name="sugarbaker-long-term">[https://www.scientificarchives.com/abstract/long-term-intraperitoneal-chemotherapy-for-malignant-peritoneal-mesothelioma Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma], Sugarbaker & Chang (2017)</ref>		<ref name="sugarbaker-long-term">[https://www.scientificarchives.com/abstract/long-term-intraperitoneal-chemotherapy-for-malignant-peritoneal-mesothelioma Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma], Sugarbaker & Chang (2017)</ref>
	<ref name="repeat-hipec">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3901297/ Outcomes of Repeat Cytoreductive Surgery with HIPEC], PMC (2014)</ref>		<ref name="repeat-hipec">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3901297/ Outcomes of Repeat Cytoreductive Surgery with HIPEC], PMC (2014)</ref>
	<ref name="vogelzang">[https://~~mesothelioma~~.~~net~~/mesothelioma~~-chemotherapy/ Mesothelioma Chemotherapy Treatment Options~~], ~~Mesothelioma~~.~~net~~</ref>		<ref name="vogelzang">[https://pubmed.ncbi.nlm.nih.gov/12860964/ Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma], Vogelzang et al., ''Journal of Clinical Oncology'' (2003)</ref>
	<ref name="pemetrexed-eap">[https://pubmed.ncbi.nlm.nih.gov/16098243/ Open-label study of pemetrexed alone or in combination with cisplatin], Jänne et al. (2005)</ref>		<ref name="pemetrexed-eap">[https://pubmed.ncbi.nlm.nih.gov/16098243/ Open-label study of pemetrexed alone or in combination with cisplatin], Jänne et al. (2005)</ref>
	<ref name="frontiers-nivo-ipi">[https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1410322/full Major response of peritoneal mesothelioma to nivolumab and ipilimumab], Frontiers in Oncology (2024)</ref>		<ref name="frontiers-nivo-ipi">[https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1410322/full Major response of peritoneal mesothelioma to nivolumab and ipilimumab], Frontiers in Oncology (2024)</ref>

MesotheliomaSupport: Fix 3 unused reference errors (dandell-compensation, mlc-prognosis, mlc-peritoneal)

2026-02-23T02:48:34Z

Fix 3 unused reference errors (dandell-compensation, mlc-prognosis, mlc-peritoneal)

← Older revision		Revision as of 02:48, 23 February 2026
Line 76:		Line 76:
	== What Is Peritoneal Mesothelioma? ==		== What Is Peritoneal Mesothelioma? ==

	Peritoneal mesothelioma arises from the '''mesothelial cells''' that line the peritoneal cavity — a thin, protective membrane that covers both the abdominal wall (parietal peritoneum) and the surface of abdominal organs including the liver, stomach, intestines, and spleen (visceral peritoneum).<ref name="kim-review" /> The peritoneum normally produces a small amount of lubricating fluid that allows organs to move smoothly against one another. When malignant mesothelioma develops in this tissue, it typically spreads diffusely across the peritoneal surfaces rather than forming a single discrete mass. This pattern of diffuse growth throughout the abdomen, rather than deep invasion into organs, is a defining characteristic that distinguishes peritoneal mesothelioma from many other abdominal malignancies and provides the rationale for the locoregional treatment approach of CRS+HIPEC.<ref name="kim-review" /><ref name="sugarbaker-long-term" />		Peritoneal mesothelioma arises from the '''mesothelial cells''' that line the peritoneal cavity — a thin, protective membrane that covers both the abdominal wall (parietal peritoneum) and the surface of abdominal organs including the liver, stomach, intestines, and spleen (visceral peritoneum).<ref name="kim-review" /><ref name="mlc-peritoneal" /> The peritoneum normally produces a small amount of lubricating fluid that allows organs to move smoothly against one another. When malignant mesothelioma develops in this tissue, it typically spreads diffusely across the peritoneal surfaces rather than forming a single discrete mass. This pattern of diffuse growth throughout the abdomen, rather than deep invasion into organs, is a defining characteristic that distinguishes peritoneal mesothelioma from many other abdominal malignancies and provides the rationale for the locoregional treatment approach of CRS+HIPEC.<ref name="kim-review" /><ref name="sugarbaker-long-term" />

	A critical clinical distinction exists between malignant peritoneal mesothelioma and two benign peritoneal conditions. '''Well-differentiated papillary mesothelioma (WDPM)''' is now recognized as a genetically distinct entity from malignant mesothelioma, defined by mutually exclusive mutations in '''TRAF7''' and '''CDC42''' — mutations that are absent in malignant mesothelioma. All WDPM cases demonstrate intact BAP1 expression by immunohistochemistry, in contrast to malignant mesothelioma where BAP1 loss occurs in approximately half of cases. The 2025 consensus guidelines recommend observation for WDPM, with intervention reserved for symptomatic, recurrent, diffuse, or microinvasive disease.<ref name="wdpm-genetics" /><ref name="consensus-2025" /> '''Multicystic peritoneal mesothelioma''' is another benign variant consisting of small cysts composed of mesothelial epithelium with bland cuboidal cells, distinguishable from malignant disease by its lack of invasion and simple architectural patterns.<ref name="rare-variants" />		A critical clinical distinction exists between malignant peritoneal mesothelioma and two benign peritoneal conditions. '''Well-differentiated papillary mesothelioma (WDPM)''' is now recognized as a genetically distinct entity from malignant mesothelioma, defined by mutually exclusive mutations in '''TRAF7''' and '''CDC42''' — mutations that are absent in malignant mesothelioma. All WDPM cases demonstrate intact BAP1 expression by immunohistochemistry, in contrast to malignant mesothelioma where BAP1 loss occurs in approximately half of cases. The 2025 consensus guidelines recommend observation for WDPM, with intervention reserved for symptomatic, recurrent, diffuse, or microinvasive disease.<ref name="wdpm-genetics" /><ref name="consensus-2025" /> '''Multicystic peritoneal mesothelioma''' is another benign variant consisting of small cysts composed of mesothelial epithelium with bland cuboidal cells, distinguishable from malignant disease by its lack of invasion and simple architectural patterns.<ref name="rare-variants" />
Line 372:		Line 372:
	\|}		\|}

	The key prognostic factors consistently identified across multiple studies include: '''completeness of cytoreduction''' (the single most important factor), '''histological subtype''' (epithelioid strongly favorable), '''PCI score''' (lower is better), '''age''' (younger patients fare better), '''lymph node involvement''' (N+ median survival 6–20 months vs. 56–59 months N-), and '''Ki-67 proliferative index''' (≤10% correlates with improved survival).<ref name="kim-review" /><ref name="baratti-long-term" /><ref name="mesonet-prognosis" />		The key prognostic factors consistently identified across multiple studies include: '''completeness of cytoreduction''' (the single most important factor), '''histological subtype''' (epithelioid strongly favorable), '''PCI score''' (lower is better), '''age''' (younger patients fare better), '''lymph node involvement''' (N+ median survival 6–20 months vs. 56–59 months N-), and '''Ki-67 proliferative index''' (≤10% correlates with improved survival).<ref name="kim-review" /><ref name="baratti-long-term" /><ref name="mesonet-prognosis" /><ref name="mlc-prognosis" />

	Notably, patients who survive 7 or more years after CRS+HIPEC appear to reach a survival plateau, with '''43.6% of patients''' in the Baratti/Deraco series remaining alive at 7+ years of follow-up — suggesting a potential cure for a substantial minority of patients.<ref name="baratti-long-term" />		Notably, patients who survive 7 or more years after CRS+HIPEC appear to reach a survival plateau, with '''43.6% of patients''' in the Baratti/Deraco series remaining alive at 7+ years of follow-up — suggesting a potential cure for a substantial minority of patients.<ref name="baratti-long-term" />
Line 452:		Line 452:
	=== Personal Injury Lawsuits ===		=== Personal Injury Lawsuits ===

	Average mesothelioma settlements range from '''$1 million–$1.4 million''', while average trial verdicts range from '''$2.4 million–$20.7 million''' depending on the source and year of data.<ref name="dandell-settlements" /><ref name="meso-atty-lawsuits" /> Notable peritoneal-specific verdicts include an '''$82 million''' Washington jury award for wrongful death from peritoneal mesothelioma caused by auto products asbestos exposure, and an '''$18 million''' 2025 Florida jury verdict for peritoneal mesothelioma.<ref name="dandell-settlements" />		Average mesothelioma settlements range from '''$1 million–$1.4 million''', while average trial verdicts range from '''$2.4 million–$20.7 million''' depending on the source and year of data.<ref name="dandell-settlements" /><ref name="dandell-compensation" /><ref name="meso-atty-lawsuits" /> Notable peritoneal-specific verdicts include an '''$82 million''' Washington jury award for wrongful death from peritoneal mesothelioma caused by auto products asbestos exposure, and an '''$18 million''' 2025 Florida jury verdict for peritoneal mesothelioma.<ref name="dandell-settlements" />

	=== VA Benefits for Veterans ===		=== VA Benefits for Veterans ===

MesotheliomaSupport: Publish full medical deep-dive page — peritoneal mesothelioma

2026-02-23T00:07:20Z

Publish full medical deep-dive page — peritoneal mesothelioma

Show changes

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T20:56:31Z

Internal linking: added 3 wiki links

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T20:53:34Z

Internal linking: added 3 wiki links

← Older revision		Revision as of 20:53, 20 February 2026
Line 45:		Line 45:
	== Executive Summary ==		== Executive Summary ==

	Malignant peritoneal mesothelioma (MPM) represents the second most common site of mesothelioma, accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref> Unlike [[Pleural Mesothelioma\|pleural mesothelioma]], which predominantly affects men with occupational [[Asbestos Exposure\|asbestos exposure]], peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented asbestos ~~exposure—a~~ distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences \| Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding [[Treatment Options\|treatment options]] beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.		Malignant peritoneal [[Mesothelioma\|mesothelioma]] (MPM) represents the second most common site of mesothelioma, accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref> Unlike [[Pleural Mesothelioma\|pleural mesothelioma]], which predominantly affects men with occupational [[Asbestos Exposure\|asbestos exposure]], peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented [[Asbestos Exposure\|asbestos exposure]]—a distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences \| Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding [[Treatment Options\|treatment options]] beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.

	== Key Facts ==		== Key Facts ==
Line 55:		Line 55:
	\| style="padding:15px;" \|		\| style="padding:15px;" \|
	* '''Disease Burden:''' 10–20% of all mesothelioma cases; approximately 315–800 new cases annually in the United States<ref name="seermeso" />		* '''Disease Burden:''' 10–20% of all mesothelioma cases; approximately 315–800 new cases annually in the United States<ref name="seermeso" />
	* '''Near-Equal Gender Distribution:''' 1.2:1 male-to-female ratio, dramatically different from pleural mesothelioma (1:7)		* '''Near-Equal Gender Distribution:''' 1.2:1 male-to-female ratio, dramatically different from [[Pleural Mesothelioma\|pleural mesothelioma]] (1:7)
	* '''Asbestos Attribution:''' 60–80% of cases have documented asbestos exposure; 20–40% occur without identifiable exposure		* '''Asbestos Attribution:''' 60–80% of cases have documented asbestos exposure; 20–40% occur without identifiable exposure
	* '''Standard Treatment:''' CRS/HIPEC achieves 5-year survival of 41–59%, compared to ~12 months with chemotherapy alone<ref name="pmcyan" /><ref name="pmchelm" />		* '''Standard Treatment:''' CRS/HIPEC achieves 5-year survival of 41–59%, compared to ~12 months with chemotherapy alone<ref name="pmcyan" /><ref name="pmchelm" />

MesotheliomaSupport: Internal linking: added 4 wiki links

2026-02-20T20:47:06Z

Internal linking: added 4 wiki links

← Older revision		Revision as of 20:47, 20 February 2026
Line 10:		Line 10:
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Peritoneal Mesothelioma		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Peritoneal [[Mesothelioma]]
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Critical facts for diagnosis and treatment		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Critical facts for diagnosis and treatment
Line 45:		Line 45:
	== Executive Summary ==		== Executive Summary ==

	Malignant peritoneal mesothelioma (MPM) represents the second most common site of mesothelioma, accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref> Unlike pleural mesothelioma, which predominantly affects men with occupational asbestos exposure, peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented asbestos exposure—a distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences \| Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding treatment options beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.		Malignant peritoneal mesothelioma (MPM) represents the second most common site of mesothelioma, accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref> Unlike [[Pleural Mesothelioma\|pleural mesothelioma]], which predominantly affects men with occupational [[Asbestos Exposure\|asbestos exposure]], peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented asbestos exposure—a distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences \| Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding [[Treatment Options\|treatment options]] beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.

	== Key Facts ==		== Key Facts ==

← Older revision		Revision as of 20:56, 20 February 2026
Line 45:		Line 45:
	== Executive Summary ==		== Executive Summary ==

	Malignant peritoneal [[Mesothelioma\|mesothelioma]] (MPM) represents the second most common site of mesothelioma, accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref> Unlike [[Pleural Mesothelioma\|pleural mesothelioma]], which predominantly affects men with occupational [[Asbestos Exposure\|asbestos exposure]], peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented [[Asbestos Exposure\|asbestos exposure]]—a distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences \| Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding [[Treatment Options\|treatment options]] beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.		Malignant peritoneal [[Mesothelioma\|mesothelioma]] (MPM) represents the second most common site of [[Mesothelioma\|mesothelioma]], accounting for 10–20% of all mesothelioma diagnoses in the United States, with approximately 315–800 new cases diagnosed annually.<ref name="seermeso">[https://www.cdc.gov/united-states-cancer-statistics/publications/mesothelioma.html Incidence of Malignant Mesothelioma, U.S. Cancer Statistics, Centers for Disease Control and Prevention]</ref><ref name="mlcdiseases">[https://www.mesotheliomalawyercenter.org/asbestos/diseases/ Asbestos-Related Diseases \| Mesothelioma Lawyer Center]</ref> Unlike [[Pleural Mesothelioma\|pleural mesothelioma]], which predominantly affects men with occupational [[Asbestos Exposure\|asbestos exposure]], peritoneal mesothelioma demonstrates a near-equal gender distribution (1.2:1 male-to-female ratio), with approximately 20–40% of cases occurring without documented [[Asbestos Exposure\|asbestos exposure]]—a distinction that reflects higher rates of secondary/paraoccupational exposure and germline genetic factors such as BAP1 mutations.<ref name="dandellperitoneal">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/pleural-vs-peritoneal-mesothelioma-differences/ Pleural vs. Peritoneal Mesothelioma: Key Differences \| Danziger & De Llano]</ref> Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care for eligible patients, extending median overall survival from approximately 12 months with chemotherapy alone to 34–92 months in selected cohorts, with 5-year survival rates of 41–59%.<ref name="pmcyan">[https://pubmed.ncbi.nlm.nih.gov/19917862/ Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. ''J Clin Oncol.'' 2009;27(36):6237-6242.]</ref><ref name="pmchelm">[https://pubmed.ncbi.nlm.nih.gov/25124472/ Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. ''Ann Surg Oncol.'' 2015;22(5):1686-1693.]</ref><ref name="mesonetperitoneal">[https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal Mesothelioma \| Mesothelioma.net]</ref> Notably, women experience superior outcomes compared to men—68% five-year survival versus 39% in men—an advantage attributed to younger age at diagnosis, better performance status, and potential hormonal protective factors.<ref name="dandellsymptoms">[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-symptoms-guide/ Mesothelioma Symptoms Guide \| Danziger & De Llano]</ref> Emerging therapies including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for palliative care and downstaging, immunotherapy with checkpoint inhibitors, and targeted approaches addressing BAP1 mutations (present in 38–45% of cases) are expanding [[Treatment Options\|treatment options]] beyond traditional CRS/HIPEC for unresectable and relapsed disease. The peritoneal cancer index (PCI) scoring system, which stratifies disease burden on a 0–39 scale, remains the most important prognostic indicator—patients with PCI ≤20 achieve five-year survival rates exceeding 50%, while those with PCI ≥30 experience dramatically reduced survival.

	== Key Facts ==		== Key Facts ==
Line 56:		Line 56:
	* '''Disease Burden:''' 10–20% of all mesothelioma cases; approximately 315–800 new cases annually in the United States<ref name="seermeso" />		* '''Disease Burden:''' 10–20% of all mesothelioma cases; approximately 315–800 new cases annually in the United States<ref name="seermeso" />
	* '''Near-Equal Gender Distribution:''' 1.2:1 male-to-female ratio, dramatically different from [[Pleural Mesothelioma\|pleural mesothelioma]] (1:7)		* '''Near-Equal Gender Distribution:''' 1.2:1 male-to-female ratio, dramatically different from [[Pleural Mesothelioma\|pleural mesothelioma]] (1:7)
	* '''Asbestos Attribution:''' 60–80% of cases have documented asbestos exposure; 20–40% occur without identifiable exposure		* '''Asbestos Attribution:''' 60–80% of cases have documented [[Asbestos Exposure\|asbestos exposure]]; 20–40% occur without identifiable exposure
	* '''Standard Treatment:''' CRS/HIPEC achieves 5-year survival of 41–59%, compared to ~12 months with chemotherapy alone<ref name="pmcyan" /><ref name="pmchelm" />		* '''Standard Treatment:''' CRS/HIPEC achieves 5-year survival of 41–59%, compared to ~12 months with chemotherapy alone<ref name="pmcyan" /><ref name="pmchelm" />
	* '''Peritoneal Cancer Index (PCI):''' Divides abdomen into 13 regions on 0–39 scale; PCI ≤20 predicts 5-year OS >50%<ref name="pmchelm" />		* '''Peritoneal Cancer Index (PCI):''' Divides abdomen into 13 regions on 0–39 scale; PCI ≤20 predicts 5-year OS >50%<ref name="pmchelm" />
Line 70:		Line 70:
	Peritoneal mesothelioma is a rare, aggressive cancer arising from the mesothelial cells that line the peritoneum—the serosal membrane of the abdominal cavity.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Malignant Mesothelioma Treatment (PDQ) – Patient Version, National Cancer Institute]</ref><ref name="mlccancer">[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer \| Mesothelioma Lawyer Center]</ref> It is the second most common site of mesothelioma development after the pleura (lung lining). The disease typically presents with non-specific abdominal symptoms including pain, distension, ascites (fluid accumulation), and weight loss, often resulting in delayed diagnosis by 4–6 months from initial symptom presentation.		Peritoneal mesothelioma is a rare, aggressive cancer arising from the mesothelial cells that line the peritoneum—the serosal membrane of the abdominal cavity.<ref name="ncimeso">[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Malignant Mesothelioma Treatment (PDQ) – Patient Version, National Cancer Institute]</ref><ref name="mlccancer">[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer \| Mesothelioma Lawyer Center]</ref> It is the second most common site of mesothelioma development after the pleura (lung lining). The disease typically presents with non-specific abdominal symptoms including pain, distension, ascites (fluid accumulation), and weight loss, often resulting in delayed diagnosis by 4–6 months from initial symptom presentation.

	The peritoneum is a thin, slippery membrane that lines the abdominal and pelvic cavities, providing a protective barrier around organs and allowing them to move freely. When asbestos fibers reach the peritoneum and become lodged in this lining, they trigger chronic inflammation and malignant transformation of mesothelial cells. The disease remains largely confined to the abdominal cavity, distinguishing it from pleural mesothelioma, which can metastasize to distant sites. Unlike pleural mesothelioma's male predominance, peritoneal mesothelioma occurs with nearly equal frequency in men and women—a distinction with significant clinical and legal implications.		The peritoneum is a thin, slippery membrane that lines the abdominal and pelvic cavities, providing a protective barrier around organs and allowing them to move freely. When asbestos fibers reach the peritoneum and become lodged in this lining, they trigger chronic inflammation and malignant transformation of mesothelial cells. The disease remains largely confined to the abdominal cavity, distinguishing it from [[Pleural Mesothelioma\|pleural mesothelioma]], which can metastasize to distant sites. Unlike pleural mesothelioma's male predominance, peritoneal mesothelioma occurs with nearly equal frequency in men and women—a distinction with significant clinical and legal implications.

	== What Causes Peritoneal Mesothelioma? ==		== What Causes Peritoneal Mesothelioma? ==